Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum. This takes time, but patient investors could score a major win by following Wood's strategy -- and by picking up a couple of her favorite stocks. Over the past several weeks, Wood has added to one of her key positions, a stock that's lost about ...

On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies. After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders.Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals (VRTX 0.13%), had hoped. Less than a year into the launch ...

Godzilla and King Kong surely weren't born big. They began small and grew over time to their gargantuan sizes even if the movies don't tell their childhood stories.Likewise, huge companies of today were once much smaller (unless perhaps they were spin-offs). Investors who spotted them early had opportunities to make fortunes.Can you still find such monsters in the making? Three Motley Fool contributors think so. Here's why they think biotech stocks CRISPR Therapeutics (CRSP 3.44%), Summit Therapeutics (SMMT ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft, I'm one of the biotech analysts at Jeffreys. I'd like to welcome Sam Kulkarni, the CEO of CRISPR Therapeutics. Sam, thanks so much for joining us today. Samarth Kulkarni Thank you for having me. Maury Raycroft And we' ...

CRISPR Therapeutics’ (CRSP) shares have lost 6.6% in the past two weeks compared with the industry’s 8.4% decline, as seen in the chart below. The stock has underperformed the sector and the S&P 500 index. Shares of the company are also currently trading below its 50-day and 200-day moving averages.CRSP Stock Performance Image Source: Zacks Investment ResearchThe drop in the share price is likely due to the decline of the drug/biotech sector in the past couple of months due to lower-than-expected third-quar ...

Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.Here are two such opportunities that are ripe for buying today, provided that you're willing to hold on to your shares for at least five years.1. CRISPR TherapeuticsWith a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (CRSP 0.85%) has an impressive resume already, but i ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here. And joining me today is Samarth Kulkarni, CEO and Chairman of CRISPR Therapeutics. ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here. And joining me today is Samarth Kulkarni, CEO and Chairman of CRISPR Therapeutics. ...

Core Insights - CRISPR Therapeutics aims to evolve from a pioneering gene therapy company into a broader biotech powerhouse over the next three years, focusing on expanding its pipeline and collaborations while still facing potential losses [1][2]. Group 1: Business Strategy and Pipeline Expansion - The company plans to initiate one or two new investigational drug programs annually, targeting new diseases and treatment areas beyond its current focus [3]. - CRISPR will continue to develop its first approved medicine, Casgevy, while also exploring new therapeutic areas such as cardiovascular disease and type 1 diabetes [4][5]. Group 2: Financial Position and Funding Needs - As of the end of Q3, CRISPR holds approximately $1.9 billion in cash and equivalents, with no debt but $210.6 million in operating lease liabilities, indicating a strong financial position [6]. - The company anticipates ongoing losses for the next few years, necessitating future capital raises through debt issuance or secondary stock sales [6]. Group 3: Collaborations and Manufacturing - CRISPR is likely to pursue more collaboration agreements, similar to its partnership with Vertex Pharmaceuticals, to leverage its strengths in genetic medicine development while outsourcing other operational aspects [7]. - The company plans to enhance its manufacturing capabilities, particularly for cell therapies, to reduce costs and streamline future product rollouts [8].

Core Insights - CRISPR Therapeutics will present at the Jefferies London Healthcare Conference on November 20, 2024, at 4:00 p.m. GMT [1] - A live webcast of the presentation will be available on the company's website, with a replay archived for 14 days [2] Company Overview - CRISPR Therapeutics has evolved from a research-stage company to a leader in gene-based medicines, recently achieving the historic approval of the first CRISPR-based therapy [3] - The company has a diverse portfolio targeting various diseases, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases [3] - The first CRISPR/Cas9 gene-edited therapy was advanced into clinical trials in 2018 for sickle cell disease and beta thalassemia, with CASGEVY (exa-cel) approved in some countries starting late 2023 [3] - CRISPR Therapeutics has established strategic partnerships with Bayer and Vertex Pharmaceuticals to enhance its research and development efforts [3] - The company is headquartered in Zug, Switzerland, with R&D operations in Boston and San Francisco, and business offices in London [3]